Myriad settles four more BRCA patent cases
This article was originally published in Clinica
Executive Summary
Myriad Genetics has settled four more patent wrangles over its BRCA gene mutation tests, with Pathway Genomics, Invitae, Ambry Genetics and LabCorp.